Esperion Therapeutics ESPR Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total Revenues by Product | |||||
| Collaboration revenue | $243.67M+24.3% | $196.09M+416% | $38M+93.8% | $19.61M-48.9% | |
| Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received | $148.8M-27.4% | $205M+451% | $37.2M+104% | $18.2M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Esperion Therapeutics break its business down?
- Esperion Therapeutics (ESPR) reports total revenues by product across 2 parts — Collaboration revenue and Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received. Each is extracted from the segment footnotes and tracked over time.
- Where does Esperion Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Esperion Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
